Who
Gregory A. Gould
CFO
Company insider
Files Form 4 as: CFO, Aclarion; Chief Financial Officer, Charlotte's Web Holdings; Chief Financial Officer, NewAge; Director, CytoDyn; Chief Financial Officer, Aytu BioPharma; Chief Financial Officer, Ampio Pharmaceuticals; Interim CEO, CFO, Treas & Sec., Seracare Life Sciences.
In numbers
- Trades disclosed
- 111
- Buys
- 2
- Sells
- 0
- Bought
- $149K
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 1
- First trade
- 20 Mar 2006
- Last trade
- 14 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 18 Aug 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $25K10,000 at $2.45 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $25K10,000 at $2.45 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Sep 2025filed 3 Sep 2025 | ACON Aclarionoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 17 Jun 2022filed 21 Jun 2022 | Charlotte's Web Holdingsoption or derivative | SEC FORM 4 Code A | —1,200,000 at $0.00 | filing |
| 2 Jul 2021filed 7 Jul 2021 | NewAge | SEC FORM 4 Code F | $164K73,110 at $2.24 | filing |
| 10 Mar 2021filed 12 Mar 2021 | NewAgeoption or derivative | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 5 Jan 2021filed 5 Jan 2021 | NewAge | SEC FORM 4 Code F | $70K26,507 at $2.63 | filing |
| 10 Dec 2020filed 11 Dec 2020 | NewAge | SEC FORM 4 Code F | $30K9,564 at $3.16 | filing |
| 22 Oct 2020filed 26 Oct 2020 | NewAge | SEC FORM 4 Code F | $26K9,564 at $2.72 | filing |
| 10 Dec 2019filed 12 Dec 2019 | New Age Beveragesoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 10 Dec 2019filed 12 Dec 2019 | New Age Beverages | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jul 2019filed 3 Jul 2019 | New Age Beveragesoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jul 2019filed 3 Jul 2019 | New Age Beverages | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jul 2019filed 3 Jul 2019 | New Age Beverages | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 18 Jun 2019filed 19 Jun 2019 | CytoDynoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 16 Nov 2018filed 19 Nov 2018 | CytoDyn | SEC FORM 4 Code A | —19,176 | filing |
| 16 Nov 2018filed 19 Nov 2018 | CytoDynoption or derivative | SEC FORM 4 Code A | —50,000 | filing |
| 16 Nov 2018filed 19 Nov 2018 | CytoDynoption or derivative | SEC FORM 4 Code A | —50,000 | filing |
News
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar DiscsACON · manilatimes.net · 22 Oct 2026Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026ACON · manilatimes.net · 20 Oct 2026
0 headlines in the last 90 days name Gregory A. Gould; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.